The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech. Johnson & Johnson expects the transaction to be operationally accretive upon closing, but considering the impact of financing costs, is expected to dilute adjusted earnings per share by approximately 10c in 2024 and approximately 17c in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Paging Dr. Nvidia (NASDAQ:NVDA): AI and Healthcare
- J&J to pay $75M to settle $6B baby powder lawsuit, Bloomberg reports
- J&J to pay $75M to settle Mississipi talc lawsuit, Bloomberg says
- Judge gives J&J new chance to contest evidence on talc products, Reuters says
- Piper says competitive process could materialize for ShockWave